版本:
中国

BRIEF-Foamix announces dosing of first patient in phase 3 rosacea clinical trials

June 12 Foamix Pharmaceuticals Ltd

* Foamix announces dosing of first patient in phase 3 rosacea clinical trials for FMX103 minocycline foam 1.5%

* Foamix Pharmaceuticals Ltd - "we expect topline data in mid-2018" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐